Iovance Biotherapeutics, a California-based clinical-stage biotechnology firm, is dedicated to developing and commercializing immunotherapy products to combat cancer by utilizing patients' immune systems. Its primary product candidate in development is lifileucel, which is currently undergoing phase II clinical trials for the treatment of metastatic melanoma and cervical cancer. The company is also working on developing other products, including LN-145 for treating metastatic non-small cell lung cancer, IOV-4001 for treating non-small cell lung and melanoma cancer, IOV-2001, and IOV-3001. Iovance Biotherapeutics has established collaborations and licensing agreements with esteemed medical institutions, such as Cellectis S.A., H. Lee Moffitt Cancer Center, Novartis Pharma AG, Melanoma Institute Australia, Beth-Israel Deaconess Medical Center, and Ohio State University. The company was previously known as Lion Biotechnologies, debuted as a public company in 2015, and later changed its name to Iovance Biotherapeutics in 2017.
Iovance Biotherapeutics's ticker is IOVA
The company's shares trade on the NASDAQ stock exchange
They are based in San Carlos, California
There are 51-200 employees working at Iovance Biotherapeutics
It is iovance.com
Iovance Biotherapeutics is in the Healthcare sector
Iovance Biotherapeutics is in the Biotechnology industry
The following five companies are Iovance Biotherapeutics's industry peers: